Eclipse Bioinnovations: Funding, Investors & Team (Sep 2026)
Eclipse Bioinnovations is a leading RNA genomics company founded in 2017 based on technology developed at the University of California, San Diego. Eclipse's mission is to use their pioneering RNA genomics platform technologies to advance RNA medicines and scientific discovery. Eclipse’s founders developed eCLIP, the world’s most efficient and unique CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse’s suite of RNA genomics technologies now cover eCLIP-RBP for mapping the RNA binding proteins, miR-eCLIP for the miR-interactome, m6A-eCLIP for RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for simplifying Crispr library prep. Products are offered as services and kit for biopharma companies and academic researchers, and can be customized for clients.
Eclipse Bioinnovations has raised $30.9M across 3 funding rounds on record, the most recent an undisclosed round of $4.9M announced in Nov 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Eclipse Bioinnovations Company Profile and Key Stats
Latest funding round on record: Nov 2025.
Eclipse Bioinnovations Funding Rounds
Eclipse Bioinnovations raised $12.0M in an undisclosed round announced in Sep 2021.
6 months later, a Series A of $14.0M was announced in Mar 2022.
3.7 years later, an undisclosed round of $4.9M was announced in Nov 2025.
Eclipse Bioinnovations Founders and Leadership Team
Contact details for the Eclipse Bioinnovations team: 1 of 1 has an email address on file.
Start 14-day free trial →Eclipse Bioinnovations Funding Compared to Other Biotechnology Startups
Eclipse Bioinnovations' latest round of $4.9M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Eclipse Bioinnovations in Biotechnology and San Diego
Companies Similar to Eclipse Bioinnovations
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Eclipse Bioinnovations Funding FAQs
What does Eclipse Bioinnovations do?
Eclipse Bioinnovations is a leading RNA genomics company founded in 2017 based on technology developed at the University of California, San Diego. Eclipse's mission is to use their pioneering RNA genomics platform technologies to advance RNA medicines and scientific discovery. Eclipse’s founders developed eCLIP, the world’s most efficient and unique CLIP-seq technology for identifying RNA binding protein gene partners and gene maps. Eclipse’s suite of RNA genomics technologies now cover eCLIP-RBP for mapping the RNA binding proteins, miR-eCLIP for the miR-interactome, m6A-eCLIP for RNA modifications, End-Seq for 5' and 3' mapping, and FLI-Seq for simplifying Crispr library prep. Products are offered as services and kit for biopharma companies and academic researchers, and can be customized for clients.
How much funding has Eclipse Bioinnovations raised?
Eclipse Bioinnovations has raised $30.9M across 3 rounds on record. The most recent is an undisclosed round of $4.9M announced in Nov 2025.
When did Eclipse Bioinnovations last raise funding?
Eclipse Bioinnovations' most recent funding round on record is an undisclosed round of $4.9M, announced in Nov 2025.
Who is the CEO of Eclipse Bioinnovations?
Peter Chu is listed as CEO at Eclipse Bioinnovations.
Where is Eclipse Bioinnovations headquartered?
Eclipse Bioinnovations is based in San Diego, California, United States.
How many employees does Eclipse Bioinnovations have?
Eclipse Bioinnovations is in the 11-50 employee band.
How does Eclipse Bioinnovations' funding compare to other Biotechnology startups?
Eclipse Bioinnovations' latest round of $4.9M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Eclipse Bioinnovations Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eclipse Bioinnovations is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.